- Home
- NXL vs XAIR Comparison
NXL vs XAIR Comparison
Compare NXL & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- XAIR
- Stock Information
- Founded
- NXL 2010
- XAIR 2011
- Country
- NXL United States
- XAIR United States
- Employees
- NXL N/A
- XAIR N/A
- Industry
- NXL Medical Specialities
- XAIR Medical/Dental Instruments
- Sector
- NXL Health Care
- XAIR Health Care
- Exchange
- NXL Nasdaq
- XAIR Nasdaq
- Market Cap
- NXL 21.0M
- XAIR 17.0M
- IPO Year
- NXL 2022
- XAIR N/A
- Fundamental
- Price
- NXL $0.98
- XAIR $0.19
- Analyst Decision
- NXL Strong Buy
- XAIR Strong Buy
- Analyst Count
- NXL 1
- XAIR 2
- Target Price
- NXL $5.00
- XAIR $1.50
- AVG Volume (30 Days)
- NXL 87.1K
- XAIR 5.4M
- Earning Date
- NXL 08-07-2025
- XAIR 08-05-2025
- Dividend Yield
- NXL N/A
- XAIR N/A
- EPS Growth
- NXL N/A
- XAIR N/A
- EPS
- NXL N/A
- XAIR N/A
- Revenue
- NXL $131,065.00
- XAIR $3,705,000.00
- Revenue This Year
- NXL $79.59
- XAIR $286.75
- Revenue Next Year
- NXL $334.65
- XAIR $144.39
- P/E Ratio
- NXL N/A
- XAIR N/A
- Revenue Growth
- NXL N/A
- XAIR 219.67
- 52 Week Low
- NXL $0.59
- XAIR $0.15
- 52 Week High
- NXL $4.49
- XAIR $0.68
- Technical
- Relative Strength Index (RSI)
- NXL 30.94
- XAIR 50.34
- Support Level
- NXL $0.89
- XAIR $0.15
- Resistance Level
- NXL $1.03
- XAIR $0.29
- Average True Range (ATR)
- NXL 0.08
- XAIR 0.03
- MACD
- NXL -0.00
- XAIR -0.00
- Stochastic Oscillator
- NXL 18.75
- XAIR 27.00
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.